- Affiliate Assistant Professor, Global Health
- Sr. Research Manager for HIV/TB, Institute for Disease Modeling
- Assistant Professor, Department of Population Health, NYU School of Medicine
Select from the following:
Anna Bershteyn, PhD is Assistant Professor in the Department of Population Health at NYU School of Medicine. She is a senior interviewer and member of the Fellowship and Programs Council of the Fannie and John Hertz Foundation, and serves on the Steering Committee of the TB Modelling and Analysis Consortium. She previously led HIV and tuberculosis research the Institute for Disease Modeling. Her modeling research focuses on HIV transmission dynamics and impact evaluation of biomedical and programmatic improvements to HIV care and prevention. She received her PhD in Materials Science and Engineering from the Massachusetts Institute of Technology, where she studied lipid self-assembly at nanoparticle surfaces as a biomimetic approach to vaccine development.
- PhD (Massachusetts Institute of Technology)
- BS (Massachusetts Institute of Technology)
- HIV Transmission
- Implementation Science
- Infectious Diseases
Akullian A, Morrison M, Garnett G, Mnisi Z, Lukhele N, Bridenbecker B, and Bershteyn A. "The Effect of 90-90-90 on HIV-1 Incidence and Mortality in the Kingdom of Eswatini." Available at SSRN 3401987, 2019.
Selinger C, Dimitrov DT, Welkhoff PA, and Bershteyn A. "The future of a partially effective HIV vaccine: assessing limitations at the population level." International Journal of Public Health, 64 (6), 2019.
Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, et al. “Implementation and applications of EMOD, an individual-based multi-disease modeling platform.” Pathogens and Disease, 76 (5), 2018
Bershteyn A, Mutai KK, Akullian AN, et al. "The influence of mobility among high-risk populations on HIV transmission in Western Kenya." Infectious Disease Modelling 3(97-106), 2018.
Kirtane AR, Abouzid O, Minahan D, Bensel T, Hill AL, Selinger C, Bershteyn A, Morgan C, et al. “Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.” Nature Communications 9(1), Jan 2018.